BPC-157: Body Protection Compound

BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It is a partial sequence of a larger protein isolated from human gastric juice and has been studied since the early 1990s in animal models of tissue injury, inflammation, and gut protection.

Structure and Stability

Unlike most peptides, BPC-157 is notably stable in gastric acid, which has supported its study via both injectable and oral routes in animals. Plasma half-life after parenteral administration in rodents is short — on the order of 30 minutes or less— yet biological effects in tissue persist well beyond plasma clearance, suggesting local receptor or growth-factor mediated activity rather than sustained systemic exposure.

Proposed Mechanisms

Preclinical literature, much of it from the laboratory of Sikiric and colleagues at the University of Zagreb, proposes several converging mechanisms:

• Angiogenesis: Upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and activation of the VEGFR2–Akt–eNOS pathway, promoting capillary formation in injured tissue (Hsieh et al., J Mol Med, 2017).
• Nitric oxide system: Modulation of NO synthesis, counteracting dysfunction induced by L-NAME and other inhibitors.
• Growth-hormone receptor expression: Increased GHR expression in tendon fibroblasts, implicated in tendon-to-bone healing models (Chang et al., J Appl Physiol, 2011).
• Gastrointestinal cytoprotection: Protection against NSAID-, alcohol-, and stress-induced ulcers and inflammatory bowel models.

Preclinical Research Areas

Animal studies have explored BPC-157 in tendon and ligament transection models, muscle crush injury, segmental bone defects, traumatic brain injury, colitis, and corneal wound healing. Across these models, treated animals frequently show accelerated functional recovery and histological improvements compared with controls. No published human clinical trials have established efficacy or safety in people.

Research Status

BPC-157 is not approved by the FDA for any indication and is classified by the World Anti-Doping Agency (WADA) as a prohibited substance under category S0 (Non-Approved Substances). It is sold strictly as a reference compound for in-vitro and preclinical laboratory research.

References

• Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632.
• Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333.
• Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780.